# Beijing Novogene Bioinformatics Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-novogene-bioinformatics-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.novogene.com
- Total disclosed funding: $105M
- Latest round: Series B (Nov 17, 2016)
- Investors on record: 3

## About

Based in Beijing, China and established in 2011, Beijing Novogene Bioinformatics Technology Co., Ltd is a gene technology developer that provides gene sequencing services and testing equipment. The company has laboratories and subsidiaries in China and 6 countries. Up to December 2020, the company has published more than 600 SCI articles in cooperation with project partners. So far, the company has obtained 208 software copyrights and 36 patents. The company was listed on the Shanghai Stock Exchange for RMB 510.6 million.

The company provides gene sequencing platform of genomics, proteomics, metabolomics. Besides, the company also provides test kits for tumor gene and gene mutation. Its partners include more than 2,600 research institutes and universities, more than 590 hospitals, and more than 1,200 pharmaceutical and agribusiness companies around the world.

The company achieved a operating revenue of RMB 1.49 billion, which decreased by 2.92% compared to 2019. The main influence for revenue drop due to COVID-19.

## Funding rounds

- Series B, Nov 17, 2016, $73M — CMB International Asset Management, CS Capital, Sigma Square Capital
- Series A, Jul 30, 2015, $32M — CS Capital

## Investors

- CS Capital — Series A, Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- Sigma Square Capital (https://capitalatlas.ai/funds/sigma-square-capital) — Series B